Main menu

Cardiovascular, Metabolic & Endocrinological Diseases (CVMED)

cardiovascular-and-metabolic-diseases

Cardiovascular diseases (CVD) remain the leading cause of global mortality, accounting for about 1 in every 2 adult deaths worldwide. Declines over the past few decades in the incidence of CVD in Western populations – mediated in part by development of acute interventions and medicines targeting lipid and blood pressure pathways – have begun to plateau, and rates of CVD in developing countries continue to increase at an alarming rate. At the same time, rates of CVD-related morbidity, heart-failure, nephropathy and peripheral vascular disease increase as more patients survive heart attacks, and the population ages. Current projections for growth in the prevalence of diabetes threaten to create a global public health crisis. WHO predicts that the worldwide prevalence of diabetes will grow from 171 million in 2000 to 373 million by 2030. In the US alone, 20.8 million (9.6%) persons aged 20 years and older have diabetes. Impaired glucose tolerance (i.e., Prediabetes) is also common with prevalence rates ranging from 6.9% in France to 14.9% in Japan and >20% in the US. Tightly linked to the global burden of diabetes are chronic kidney disease, end-stage renal disease and heart failure. Contemporary estimates suggest that over 40 million people in the US, and over 120 million people in China alone, have impaired renal function. This threat of a global health crisis is augmented by the high rates of obesity seen in many parts of the world. Pfizer scientists are eager to work with world-class partners who share our mission to develop novel and differentiated medicines to improve the lives of patients suffering from cardiovascular and metabolic diseases, including diabetes, renal and related co-morbidities around the world.

WRD is interested in establishing partnerships to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:

  • CV-risk (ACS, peripheral vascular disease, stroke, atherosclerosis, and heart failure) in non-diabetic and diabetic through improvement in vascular function, protection or repair, reduced vascular inflammation, dyslipidemia, or enhanced cardiac repair and performance
  • Blood pressure in difficult to treat hypertensives
  • Prevention of renal disease in non-diabetics & diabetics
  • Centrally-acting anoretics
  • Bariatric surgery mimetics
  • Solute transporters and their role in metabolic and in renal disease
  • Kidney podocyte architecture
  • The progression of co-morbidities related to T2D, specifically peripheral vascular disease and heart failure
  • Insulin sensitization with weight loss
  • Beta-cell function and survival in obesity and T2D
  • Dysregulation of alpha-cell function
  • Metabolic adaptations to exercise which protect against or reverse diabetes
  • Mechanisms which protect mitochondria under conditions of chronic caloric excess
  • Lipid content and the development of liver fibrosis in patients with NASH / NAFLD
  • Dysregulation of liver metabolism
  • Weight-loss approaches to shift negative energy balance, e.g. modulators of beige and brown fat metabolism
  • Gut and brain signals that regulate energy homeostasis and metabolism
  • The role of sleep and circadian rhythm in regulating endocrine function & metabolism

External R&D Innovation Contacts: Barry Ticho or Joachim Fruebis.

R & D Brochure

callout-placeholder

Understand what R&D is looking for in an early stage opportunity.

 

Connect With Us

callout-placeholder

Reach out. We want to hear from you.